Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer

Gynecologic Oncology

Volumn 111, Issue 3, 2008, Pages 467-473

  Herzog, Thomas J ^b   Powell, Matthew A ^a   Rader, Janet S ^a   Gibb, Randall K ^a   Lippmann, Lynne ^a   Coleman, Robert L ^c   Mutch, David G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b College of Physicians and Surgeons ^*  (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Navelbine; Recurrent ovarian cancer; Topotecan

Indexed keywords

NAVELBINE; TOPOTECAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; KAPLAN MEIER METHOD; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; OVARY CANCER; PAIN; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SKIN MANIFESTATION; THROMBOEMBOLISM; TREATMENT OUTCOME; UTERINE TUBE CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TOPOTECAN; VINBLASTINE;

EID: 56749161697     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.08.005     Document Type: Article

References (21)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics 2008. CA Cancer J Clin 58 2 (2008) 71-96
2. DiSaia P.J., and Creasman W.T. Clinical Gynecologic Oncology. 6th ed (2002), C.V. Mosby Company, St. Louis
3. Ten Bokkel Huinink W., Gore M., Carmichael J., et al. Topotecan versus paclitaxel for the treatment or recurrent ovarian cancer. J Clin Oncol 15 (1997) 2183-2193
4. Gordon N., Fleagle J.T., Guthrie D., et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19 (2001) 3312-3322
5. Swisher E.M., Mutch D.G., Rader J.S., Elbendary A., and Herzog T.J. Topotecan in platinum and paclitaxel-resistant ovarian cancer. Gynecol Oncol 66 (1997) 480-486
6. Hoskins P., Eisenhauer E., Beare S., Roy M., Drouin P., Start G., et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 16 (1998) 2233-2237
7. Rose P., Gordon N., Fusco N., Fluellen L., Rodriguez M., Ingalls S., et al. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. Gynecol Oncol 78 (2000) 228-234
8. Levy T., Inbar M., Menczer J., Grisaru D., Glezerman M., and Safra T. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol 95 3 (2004) 686-690
9. Herzog T.J., Powell M.A., Rader J.S., Gibb R., and Mutch D.G. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol 103 2 (2006) 637-641
10. Burger R.A., DiSaia P.J., Roberts J.A., et al. Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol 72 2 (1999) 148-153
11. Besenval M., Delgado M., Demarez J.P., and Krikorian A. Safety and tolerance of navelbine in phase I-II clinical studies. Semin Oncol 6 2 Suppl (1989) 37-40
12. Goa K.L., and Faulds D. Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy. Drugs Aging 5 3 (1994) 200-234
13. Stupp R., Bodmer A., Duvoisin B., Bauer J., Perey L., Bakr M., et al. Is cisplatin required for the treatment of non-small-cell lung cancer? Experience and preliminary results of a phase I/II trial with topotecan and vinorelbine. Oncology 61 Suppl 1 (2001) 35-41
14. Vivacqua RJ, Lebedda J, Keogh W, Soojian M. Phase I/II study of sequential interferon alpha-2b (IFN-α2b) and weekly topotecan/vinorelbine in advanced non-small cell lung cancer (NSCLC) Abstract - 2721 Proceedings ASCO, 2002.
15. Webb M.S., Johnstone S., Morris T.J., Kennedy A., Gallagher R., Harasym N., et al. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. Eur J Pharm Biopharm 65 3 (2007) 289-299
16. Chou T.C., Motzer R.J., Tong Y., and Bosl G.J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86 20 (1994) 1493-1495
17. Rustin G.J., Nelstrop A.E., et al. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol 18 8 (2000) 1733-1739
18. Herzog T.J. Recurrent ovarian cancer: how important is it to treat to disease progression?. Clin Cancer Res 10 (2004) 7439-7449
19. Herzog T.J. The current treatment of recurrent ovarian cancer. Curr Oncol Rep 8 6 (2006) 448-454 Review
20. Parmar, M.K., et al., Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 9375 (2003) 2099-2106
21. Pfisterer J., Plante M., Vergote I., et al. Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. J Clin Oncol 24 (2006) 4699-4707